Sensitive skin is now one of the most common skin concerns, affecting nearly 70 per cent of people worldwide. Sensitive skin cases have increased dramatically in 20 years, raising questions about the impact of modern lifestyles and environmental changes. Galderma has been actively studying this trend through its Global Sensitive Skin Faculty, which is a group of leading dermatology experts. ...
Galderma showcased significant updates across its dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting. The company reinforces its leadership commitment in dermatology innovation with 22 scientific presentations, including two oral e-posters. Nemluvio Nemolizumab (Nemulizumab), Galderma’s treatment for prurigo nodularis and atopic dermatitis, was a key focus at AAD 2025. A new oral presentation showcases Nemluvio’s efficacy ...